Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.

  1. Oligonucleotide Enzyme Surrogate (OnES)

    SBC: Accacia International LLC            Topic: CBD08108

    Historically organophosphorus compounds such as insecticides and nerve agents have been susceptible to decomposition by proteinaceous enzymes. Organophosphate hydrolases (OPH) represent a practical method to deactivate such compounds peripherally and on surfaces. However, when such organophosphates are ingested, the use of proteinaceous enzymes such as OPH can be problematic because of their tende ...

    SBIR Phase I 2008 Department of DefenseOffice for Chemical and Biological Defense
  2. Carbon Nanotube-Based Filters for Aerosol Sample Collection

    SBC: AGAVE BIOSYSTEMS INC.            Topic: CBD07111

    Aerosols represent one of the more efficient methods to distribute biological and chemical agents throughout the atmosphere. Small aerosol droplets can be readily inhaled and easily penetrate deep into the lungs where they lodge in bronchial alveoli. Within the alveoli, chemical and biological agents can breach epithelial and endothelial cell layers and enter the bloodstream, where they cause da ...

    SBIR Phase I 2007 Department of DefenseOffice for Chemical and Biological Defense
  3. Ribozymes for In Vivo Degradation of G-Nerve Agents

    SBC: AGAVE BIOSYSTEMS INC.            Topic: CBD08108

    Given the possibility to administer prophylactic doses of protein bioscavengers inactivating OP nerve agents before they reach their acetylcholinesterase target, much attention has been given to proteins such as human butyrylcholinesterase and paraoxonase I. As small nucleic acid catalysts can exhibit triphosphoesterase activities, the identification of new molecules active against nerve agents w ...

    SBIR Phase I 2008 Department of DefenseOffice for Chemical and Biological Defense
  4. Collective Protection for Military Working Dogs

    SBC: AGAVE BIOSYSTEMS INC.            Topic: CBD08103

    Shelter enclosures for military working dogs in the event of a CB attack is a technology gap identified by the Joint Requirements Office. Important parameters to consider in the design of protective enclosures include low weight and size to minimize transport requirements; rapid setup; and accommodation of canine physiological and psychological comfort needs. The overall operational weight of th ...

    SBIR Phase I 2008 Department of DefenseOffice for Chemical and Biological Defense
  5. Multiple Indication Adjuvants

    SBC: BIOPROTECTION SYSTEMS CORP.            Topic: CBD08105

    The objective of this study is to demonstrate the efficacy and broad applicability of the human immune-modulating alphaGal Adjuvant Technology for antiviral vaccine development. We will use viral vaccine candidates for the select Category A viral pathogens Zaire ebolavirus (ZEBOV, filovirus), Rift Valley fever virus (RVFV, bunyavirus), and Lassa virus (LV, arenavirus), to evaluate the adjuvant pot ...

    SBIR Phase I 2008 Department of DefenseOffice for Chemical and Biological Defense
  6. Development of a Database Management System to Enable Rapid, Efficient Assay Design for Use in Detection and Diagnosis of Human Exposure to Biological

    SBC: CFD Research Corporation            Topic: CBD07114

    The primary objective of this effort is to design and develop a database management system (DBMS) and enable the integrated interpretation of the vast amounts of genomic and proteomic data in proper biological context. This DBMS will enable the development of diagnostic assays for human exposure to specific biological threat agents using an existing suite of systems biology tools. The DBMS design ...

    SBIR Phase I 2007 Department of DefenseOffice for Chemical and Biological Defense
  7. Mass Customization Biomanufacturing Process

    SBC: Chesapeake Perl, Inc.            Topic: N/A

    "Chesapeake PERL, Inc aims to develop baculovirus-based expression in insect larvae from bench-scale to mass manufacturing. The technology platform consists of automated mass insect rearing, and inoculation combined with monitoring of protein expressionlevels in larvae via a fluorescent reporter. This allows the development of "mass customization" for recombinant protein manufacturing in insect ...

    SBIR Phase I 2002 Department of DefenseOffice for Chemical and Biological Defense
  8. Automated Preferential Display for the Analysis of Gene Expression Profiles

    SBC: GENEXPRESS INFORMATICS, INC.            Topic: N/A

    "GeneXpress Informatics, Inc. (GXI) and Dr. James P. Chambers of UTSA propose to develop a revolutionary differential gene display technology, called Preferential Display (PD) which will provide for a simplified, cost-effective method to identify thesegenes for use in discovering gene expression profiles without having any prior knowledge of an organism, tissue or biological samples' genome. The ...

    SBIR Phase I 2002 Department of DefenseOffice for Chemical and Biological Defense
  9. New DNA/RNA Sequencer for Rapid Assessment of Exposure to Infectious Agents

    SBC: Lynntech Inc.            Topic: N/A

    "The importance of DNA/RNA-based assays for detection of biological warfare agents, identification of diseases, genome sequencing, and environmental control is enormous and will inevitably increase. The challenge is the development of low cost andportable methods for sequencing DNA and RNA extracted from surfaces and fluids, to recognize exposure to biowarfare agents. All the conventional techn ...

    SBIR Phase I 2002 Department of DefenseOffice for Chemical and Biological Defense
  10. Blood Brain Barrier (BBB) Permeable Encapsulating Agents for Effective Delivery of CNS-active Agents

    SBC: Lynntech Inc.            Topic: CBD08107

    Drug transport in the central nervous system is highly regulated by the Blood-Brain Barrier (BBB). Most medicines, including many for treating cancer, Alzheimer’s, and stroke, do not meet essential criteria, such as lipophilicity and low molecular weight, required for appreciable transport into the brain. However, endogenous peptides, such as insulin or transferrin, and certain monoclonal anti ...

    SBIR Phase I 2008 Department of DefenseOffice for Chemical and Biological Defense
US Flag An Official Website of the United States Government